Which issues – in terms of our corporate responsibility – are of particular significance to our long-term success? And what expectations do have of our company? In an effort to answer these questions, we regularly conduct materiality assessments that aim to rate sustainability topics according to their importance to our company and external stakeholders. This allows us to align our business activities with their priorities. In applying this approach, we fulfill the requirements of the Global Reporting Initiative (GRI), the international framework on which we’ve based this CR Report, as well as meeting the obligation arising from the CSR Directive Implementation Act that was ratified in Germany in 2017. Consequently, in 2017 we reviewed the results of the comprehensive materiality assessment we conducted in 2016 to ensure they were still up-to-date and relevant.

Validating material issues

In 2016, we conducted a comprehensive materiality assessment in which we evaluated media reports, inquiries from investors and sustainability ratings. We then weighted the issues based on the results of stakeholder surveys and interviews with experts. Both this process and the findings from the materiality assessment were reviewed by internal specialists and the CR Committee.

In 2017, the 43 key issues identified in the 2016 materiality assessment were reviewed and validated by experts from the respective business sectors. In doing so, we took account of the latest developments, updating the analysis where necessary.

Our stakeholders rate product responsibility as very important, including product quality, the safety of chemical products, innovation, and research & development. In terms of issues relevant to our company, two additional topics were identified as a result of the validation process: capacity building was deemed an important component of increasing health awareness and our experts also identified genome editing as a key aspect of bioethics. Both topics have been integrated into the relevant sections.

The topics rated as material form the focus of this CR Report. Since our also expect information and transparency from us regarding less significant issues, we also report on these, albeit in less detail.

Identifying issues for non-financial disclosure

The German CSR Directive Implementation Act obliges us to review the “double materiality” of topics according to Section 289 (3) of the German Commercial Code. The principle of double materiality requires companies to disclose non-financial information when the following two criteria are met: Firstly, the information is necessary to understand the company’s business performance, business results and financial situation. And secondly, the information makes it possible to understand how the company’s business activities affect non-financial aspects. We have reviewed the double materiality of the issues validated in 2017, which were identified in the 2016 materiality assessment. The issues that fall within the scope of this definition are marked in the materiality matrix.

Material topics

Close

Ethical conduct

* Part of the non-financial report

Close

Environmental stewardship

* Part of the non-financial report

  • Very high importance
  • High importance
  • Medium importance

Material issues in our value chain

The following table shows where our main issues fall within the value chain: upstream in our supply chain, in the course of our own activities, or downstream with customers and patients. Moreover, we have listed the issues to show the breakdown of materiality by business sector and stakeholder group. These topics are linked to the respective chapters in this report.

Activities of Merck KGaA, Darmstadt, Germany
Upstream
activities
Healthcare
Life Science
Performance Materials
Downstream
activities

Product safety and quality

Chemical product safety
0
X
X
X
X

Material for:

Customers, Merck family, Shareholders, Government agencies, NGOs, Commercial and business associates

Patient safety
0
X
0
0
X

Material for:

Merck family, Shareholders, Government agencies, NGOs, Health systems, Patients

Counterfeit products
0
X
0
0
X

Material for:

Customers, Merck family, Shareholders, Federations and policy makers, Government agencies, NGOs, Commercial and business associates, Health systems, Patients

Transport and warehouse safety
X
0
X
X
X

Material for:

Customers, Government agencies, Suppliers, Commercial and business associates, Communities

Labeling of chemicals and other products
0
X
X
X
X

Material for:

Customers, Federations and policy makers, Government agencies, NGOs, Media, Suppliers, Scientists, Commercial and business associates, Health systems, Communities, Competitors

Pharmaceutical and chemical residues in the environment
0
X
X
X
X

Material for:

Federations and policy makers, Government agencies, NGOs, Communities

Ethical conduct

Bioethics
0
X
X
0
X

Material for:

Customers, Federations and policy makers, Government agencies, NGOs, Scientists

Clinical studies
X
X
0
0
X

Material for:

Merck family, Shareholders, Federations and policy makers, Government agencies, NGOs, Media, Suppliers, Scientists, Patients

Animal welfare
X
X
X
X
0

Material for:

Government agencies, NGOs, Media, Suppliers, Scientists

Good business practice

Compliance
X
X
X
X
X

Material for:

Employees, Merck family, Shareholders, Government agencies, NGOs, Suppliers, Commercial and business associates, Health systems, Competitors

Responsible marketing
0
X
X
X
X

Material for:

Customers, Federations and policy makers, Media, Commercial and business associates, Health systems, Patients

Community involvement
0
X
X
X
X

Material for:

Merck family, NGOs, Media, Communities

Interactions with health systems
0
X
0
0
X

Material for:

Federations and policy makers, Government agencies, NGOs, Health systems, Patients

Governance
0
X
X
X
0

Material for:

Employees, Employee representatives, Merck family, Shareholders, Government agencies

Health for everyone

Access to health
X
X
X
0
X

Material for:

NGOs, Media, Suppliers, Commercial and business associates, Health systems, Patients

Prices of medicines
0
X
0
0
X

Material for:

Merck family, Shareholders, Government agencies, NGOs, Media, Commercial and business associates, Health systems, Patients

Medicines to combat rare and neglected diseases
0
X
X
0
X

Material for:

NGOs, Scientists, Health systems, Patients

Health awareness
0
X
0
0
X

Material for:

NGOs, Media, Scientists, Commercial and business associates, Health systems, Patients, Communities, Competitors

Supply chain standards

Supply chain standards
X
X
X
X
X

Material for:

Customers, Merck family, Shareholders, Federations and policy makers, NGOs, Media, Suppliers, Competitors

Human rights

Human rights
X
X
X
X
X

Material for:

Customers, Federations and policy makers, NGOs, Media, Suppliers, Communities

Sustainable products

Sustainable product design
0
0
X
X
X

Material for:

Customers, Scientists

Re-use and recycling of our customers’ waste
0
0
X
0
X

Material for:

Customers

Attractive employer

Diversity and equal opportunity
0
X
X
X
0

Material for:

Employees, Employee representatives, Merck family, Media

Attracting, recruiting and retaining employees
0
X
X
X
0

Material for:

Employees, Employee representatives, Shareholders, Competitors

Employee development
0
X
X
X
0

Material for:

Employees, Employee representatives

Good leadership
0
X
X
X
0

Material for:

Employees, Employee representatives

Employee engagement
0
X
X
X
0

Material for:

Employees, Employee representatives

Health and safety
0
X
X
X
0

Material for:

Employees, Employee representatives, Government agencies

Technology

Innovation and R&D
0
X
X
X
0

Material for:

Customers, Merck family, Shareholders, Scientists, Health systems, Patients

Resource efficiency

Waste and recycling
0
X
X
X
X

Material for:

Government agencies, NGOs, Communities

Water management
0
X
X
X
X

Material for:

Government agencies, NGOs, Communities

Climate change

Energy efficiency and renewable energy
0
X
X
X
0

Material for:

Federations and policy makers, NGOs

Greenhouse gas emissions
X
X
X
X
X

Material for:

Customers, Federations and policy makers, Government agencies, NGOs, Media, Suppliers

Stakeholder
People or organizations that have a legitimate interest in a company, entitling them to make justified demands. Stakeholders include people such as employees, business partners, neighbors in the vicinity of our sites, and shareholders.
Stakeholder
People or organizations that have a legitimate interest in a company, entitling them to make justified demands. Stakeholders include people such as employees, business partners, neighbors in the vicinity of our sites, and shareholders.

Cookie Disclaimer

This website uses 'cookies' to give you the best, most relevant experience. Using this website means you’re OK with this. You can change which cookies are set at any time - and find out more about them in our cookie policy. Privacy Statement